Renal Cell Carcinoma (RCC) – Reviews and Forecast

1
EpiCast Report Renal Cell Carcinoma -
Epidemiology Forecast to 2023
Telephone [phone]Mail at
sales_at_researchbeam.com
(Type, Mode of action, Crop Type and Geography) -
Size, Share, Global Trends, Company Profiles,
Demand, Insights, Analysis, Research, Report,
Opportunities, Segmentation and Forecast, 2013 -
2020
Published on Oct 2014
2


Report Overview

• Renal cell carcinoma (RCC) is a type of kidney
  cancer that originates in the lining of the
  proximal convoluted tubule, a part of the very
  small tubes in the kidney that transport waste
  molecules from the blood to the urine. RCC is the
  most common type of kidney cancer in adults,
  being responsible for approximately 90 of all
  cases in adults. The condition is asymptomatic in
  its initial stages, and as a result, people with
  RCC are often in the advanced stages of the
  disease by the time it is discovered. The initial
  symptoms of RCC often include blood in the urine,
  flank pain, a mass in the abdomen or flank,
  weight loss, fever, hypertension, night sweats,
  and a general feeling of being unwell. Kidney
  cancer is among the 10 most frequently occurring
  cancers in Western countries. Globally, about
  270,000 cases of kidney cancer are diagnosed
  yearly, and 116,000 people die from the disease.
• The epidemiologists forecast an increase in the
  diagnosed incident cases of RCC in the 8MM, from
  190,147 diagnosed incident cases in 2013 to
  309,734 diagnosed incident cases in 2023, with an
  Annual Growth Rate (AGR) of 6.29 during the
  forecast period. In 2023, urban China will have
  the highest number of diagnosed incident cases of
  RCC in the 8MM, with 147,457 diagnosed incident
  cases, whereas Spain will have the lowest number
  of diagnosed incident cases of RCC, with 7,591
  diagnosed incident cases. Similarly, as shown in
  the second figure below, the five-year diagnosed
  prevalent cases of RCC in the 8MM will increase
  from 600,261 diagnosed prevalent cases in 2013 to
  966,190 diagnosed prevalent cases in 2023, with
  an AGR of 6.10 during the forecast period. The
  increase in the diagnosed five-year prevalent
  cases of RCC is partly attributed to the rising
  trend in the incidence rate of RCC in the 8MM,
  combined with changes in the population
  demographics in the respective markets. The
  rising trend in the incidence of RCC may partly
  be a result of increased use of imaging
  techniques that can detect asymptomatic tumors.

3


Report Overview

• Scope
• - The Renal cell carcinoma (RCC) EpiCast Report
  provides an overview of the risk factors,
  comorbidities, and the global and historical
  trends for RCC in the eight major markets (8MM)
  (US, France, Germany, Italy, Spain, UK, Japan,
  and urban China). It includes a 10-year
  epidemiological forecast for the diagnosed
  incident cases of RCC, segmented by age (at
  20-year intervals, starting at age 20 years and
  ending at ages 80 years) and sex. It also
  includes a forecast of the five-year diagnosed
  prevalent cases of RCC in the 8MM. Additionally,
  it provides the RCC diagnosed incident cases,
  segmented by the stage at diagnosis, for the 8MM.
• The RCC epidemiology report is written and
  developed by Masters- and PhD-level
  epidemiologists.
• The EpiCast Report is in-depth, high quality,
  transparent and market-driven, providing expert
  analysis of disease trends in the 8MM.
• Reasons to buy
• The RCC EpiCast report will allow you to -
• - Develop business strategies by understanding
  the trends shaping and driving the global RCC
  market.
• - Quantify patient populations in the global RCC
  market to improve product design, pricing, and
  launch plans.
• - Organize sales and marketing efforts by
  identifying the age groups and sex that present
  the best opportunities for RCC therapeutics in
  each of the markets covered.

4


Table of Contents
1 Table of Contents 4 1.1 List of Tables 6 1.2
List of Figures 7 2 Introduction 8 2.1 Catalyst
8 2.2 Upcoming Related Reports 8 3 Epidemiology
9 3.1 Disease Background 9 3.2 Risk Factors and
Comorbidities 10 3.3 Global Trends 12 3.3.1
Incidence 12 3.3.2 Survival Rates for RCC - 8MM
14 3.4 Forecast Methodology 15 3.4.1 Sources Used
17 3.4.2 Sources Not Used 20 3.4.3 Forecast
Assumptions and Methods, RCC Diagnosed Incident
Cases 21 3.5 Epidemiological Forecast for RCC
(2013-2023) 23 3.5.1 Diagnosed Incident Cases of
RCC 23 3.5.2 Age-Specific Diagnosed Incident
Cases of RCC 25 3.5.3 Sex-Specific Diagnosed
Incident Cases of RCC 27 3.6 Discussion 33 3.6.1
Epidemiological Forecast Insight 33 4 Appendix 36
5


Report Ordering
Report Name EpiCast Report Renal
Cell Carcinoma - Epidemiology Forecast to
2023
Product Price
User Price
Single User US 3396
Site User US 7990
Global User US 11985
To View Sample or Purchase Report
6



Contact Us
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/epicast-report-renal-c
ell-carcinoma-epidemiology-forecast-to-2023-market
Stay With Us At
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] DIRECT 1 (503)
894-6022E-MAIL sales_at_researchbeam.com